慢阻肺急性加重入院时血嗜酸性粒细胞计数与住院及1年死亡的关系
这项回顾性研究纳入英国六家医院连续收治的2645例经呼吸专科医师确诊的慢阻肺急性加重患者,评估入院时嗜酸性粒细胞计数与住院死亡及1年死亡的关系。结果显示52%患者入院时存在嗜酸性粒细胞减少,其住院死亡风险较无减少者升高2.5倍(12.1% vs 4.9%)。作者提示不应使用急性加重期嗜酸性粒细胞结果指导吸入糖皮质激素决策。
要点
- 慢阻肺急性加重入院时嗜酸性粒细胞减少常见,占52%。
- 嗜酸性粒细胞减少者住院死亡风险升高2.5倍(12.1% vs 4.9%)。
- 不应以急性加重期嗜酸性粒细胞结果指导吸入糖皮质激素使用。
核心结论
- 重度慢阻肺急性加重时嗜酸性粒细胞减少常见,并与住院死亡及多项急性病情标志物相关。
- 临床医生应谨慎使用重度急性加重期间获得的嗜酸性粒细胞结果来指导吸入糖皮质激素治疗决策。
研究设计与样本
- 回顾性研究,纳入英国六家医院连续收治的2645例慢阻肺急性加重患者,临床诊断由呼吸专科医师确认。
- 评估入院嗜酸性粒细胞计数与住院死亡及1年死亡的关系,并用Poisson回归分析嗜酸性粒细胞减少与急性病情标志物的关联。
主要发现
- 2645例中1369例(52%)入院时存在嗜酸性粒细胞减少。
- 嗜酸性粒细胞减少者住院死亡风险为无减少者的2.5倍(12.1% vs 4.9%,RR=2.50,95%CI 1.88至3.31,p<0.001)。
- 肺炎性加重亚组(n=788)中嗜酸性粒细胞减少者住院死亡率为21.3% vs 8.5%(RR=2.5,95%CI 1.67至2.24,p<0.001)。
- 回归分析中嗜酸性粒细胞减少与高龄、男性、较高脉率、体温、中性粒细胞计数、尿素和C反应蛋白水平、较高比例胸部X线实变和格拉斯哥昏迷评分降低相关。
- 嗜酸性粒细胞减少还与较低收缩压和舒张压、较低氧饱和度、白蛋白、血小板及既往入院次数相关。
临床怎么用
- 慢阻肺急性加重入院时应关注血嗜酸性粒细胞计数,嗜酸性粒细胞减少提示住院死亡风险升高。
- 避免根据重度急性加重期间的嗜酸性粒细胞结果决定是否使用吸入糖皮质激素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Blood eosinophil counts have been studied in patients with stable chronic obstructive pulmonary disease (COPD) and are a useful biomarker to guide inhaled corticosteroid use. Less is known about eosinophil counts during severe exacerbation. METHODS: In this retrospective study, 2645 patients admitted consecutively with COPD exacerbation across six UK hospitals were included in the study, and the clinical diagnosis was confirmed by a respiratory specialist. The relationship between admission eosinophil count, inpatient death and 1-year death was assessed. In a backward elimination, Poisson regression analysis using the log-link function with robust estimates, patients' markers of acute illness and stable-state characteristics were assessed in terms of their association with eosinopenia. RESULTS: 1369 of 2645 (52%) patients had eosinopenia at admission. Those with eosinopenia had a 2.5-fold increased risk of inpatient death compared with those without eosinopenia (12.1% vs 4.9%, RR=2.50, 95% CI 1.88 to 3.31, p<0.001). The same mortality risk with eosinopenia was seen among the subgroup with pneumonic exacerbation (n=788, 21.3% vs 8.5%, RR=2.5, 95% CI 1.67 to 2.24, p<0.001). In a regression analysis, eosinopenia was significantly associated with: older age and male sex; a higher pulse rate, temperature, neutrophil count, urea and C reactive protein level; a higher proportion of patients with chest X-ray consolidation and a reduced Glasgow Coma Score; and lower systolic and diastolic blood pressure measurements and lower oxygen saturation, albumin, platelet and previous admission counts. DISCUSSION: During severe COPD exacerbation, eosinopenia is common and associated with inpatient death and several markers of acute illness. Clinicians should be cautious about using eosinophil results obtained during severe exacerbation to guide treatment decisions regarding inhaled corticosteroid use.
引用
- Echevarria, Steer, Prasad, et al. Admission blood eosinophil count, inpatient death and death at 1 year in exacerbating patients with COPD. Thorax. 2023. PMID: 37487711. doi:10.1136/thorax-2022-219463
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。